Opleiding van jonge wetenschappers in de biologische regulatie van het chemokinenetwerk om de behandeling van ACTIEVE ontstekingen te verbeteren KU Leuven
A number of pharmaceuticals targeting cytokine/chemokine storms in lungs are in development due to an urgent new unmet medical need strengthened by the COVID-19 pandemic. The recent death of > 6.5 million people shows that treating excessive inflammation is still a major problem. Our incomplete understanding of complex immune reactions and resulting doubts on correct drug target identification prohibit efficient drug development and ...